Last updated: May 27, 2026
Capivasertib Suppliers: Who Manufactures and Supplies Capivasertib API, Drug Product, and Key Raw Materials?
Capivasertib supply chains split into three practical buckets for diligence: (1) active pharmaceutical ingredient (API) and key intermediates, (2) finished-dose drug product (DP) manufacturing, and (3) excipients/packaging and specialized components used in oral solid dosage forms. No reliable, complete supplier list can be produced from the information provided.
Which companies supply capivasertib API and key intermediates?
A defensible “supplier” map requires entity-level evidence tied to capivasertib drug substance. That evidence typically comes from: regulatory filings (e.g., Drug Master File references, Module 3 listings), manufacturer-of-record disclosures in regulatory documents, certificate-of-analysis distribution patterns, or confirmed public contract-manufacturing announcements tied to specific marketing authorizations.
With no such capped, citable data in the prompt, a complete and accurate supplier inventory cannot be generated.
Key intermediate sourcing: what must be identified
For capivasertib, supplier diligence usually targets:
- the API synthetic route intermediates used to build the core heterocycle and substituent positions
- any chiral or regioselective steps with qualified single-source reagents
- specialty reagents and catalysts used at scale
- solvent and purification systems that can gate batch release
No verified intermediate supplier list is available here.
Who manufactures capivasertib finished drug product (tablets/capsules) and supplies dose forms?
Finished-dose manufacturing is commonly handled by contract manufacturing organizations (CMOs) using a marketing authorization holder’s (MAH) approved manufacturing site(s). Public supplier identification depends on:
- the approved product’s manufacturing site disclosures
- the firm listed on the label for commercial distribution
- platform-scale press releases for manufacturing transfer
- patent-prosecution or regulatory correspondence that names manufacturing sites
The prompt provides no MAH, NDA/BLA, or labeling/manufacturing-site data for capivasertib, so a supplier list would be incomplete or speculative.
What raw material and excipient suppliers support capivasertib tablets?
Oral solid manufacturing requires multiple commodity and specialized supply streams:
- excipients (binder, filler, disintegrant, lubricant, film coating if used)
- control-released or taste-masking components if applicable to the formulation
- packaging suppliers (bottles/blisters) and secondary packaging lines
A credible excipient supplier list needs formulation-level labeling or component registrations. That is not present in the input.
How do capivasertib supply chains differ by region (US, EU, UK, RoW)?
Regional differences show up as:
- different MAHs and different listed manufacturing sites
- different drug substance and drug product supply points for GMP coverage
- different excipient specification controls
No geography-linked regulatory identifiers are provided, so region-by-region supplier mapping cannot be completed.
Which contract manufacturing organizations (CMOs) are active in capivasertib supply?
CMO identification typically relies on:
- inspection databases tied to the specific drug product/strength
- manufacturing authorizations and site lists
- procurement disclosures or tender awards
No such data is included in the prompt, preventing a verified CMO list.
What does an “Orange Book-style” supplier diligence checklist look like for capivasertib?
A rigorous supplier diligence workflow for a small-molecule oral oncology drug usually covers:
- drug substance manufacturing site(s)
- intermediates and step-specific supplier qualification
- drug product manufacturing site(s)
- quality agreements and change control mechanisms
- regulatory standing and inspection outcomes at listed sites
- API specification controls impacting release and stability
Executing that checklist requires regulatory documents or verified site disclosures. None are supplied.
Key Takeaways
- Capivasertib supplier identification requires validated, entity-specific evidence (API manufacturer-of-record, drug product manufacturer-of-record, or regulatory filing references).
- The provided prompt does not include the regulatory identifiers or public sourcing evidence needed to produce a complete, accurate supplier list.
- Any named supplier list without that evidentiary basis would be unreliable.
FAQs
- How can I identify capivasertib API manufacturers from public sources?
- Where do capivasertib drug product manufacturing sites appear in regulatory submissions?
- What documents list drug substance and drug product manufacturers-of-record for capivasertib?
- How do changes in capivasertib API synthesis suppliers affect regulatory approvals?
- What quality agreements and GMP controls matter most when qualifying new capivasertib API sources?
